Nanostructured lipid carrier system for topical delivery of terbinafine hydrochloride  by Gaba, Bharti et al.
Bulletin of Faculty of Pharmacy, Cairo University (2015) 53, 147–159HO ST E D  BY
Cairo University
Bulletin of Faculty of Pharmacy, Cairo University
www.elsevier.com/locate/bfopcu
www.sciencedirect.comORIGINAL ARTICLENanostructured lipid carrier system for topical
delivery of terbinafine hydrochloride* Corresponding author at: Department of Pharmaceutics, Faculty
of Pharmacy, Jamia Hamdard, Hamdard Nagar, New Delhi 110 062,
India. Tel.: +91 9811312247; fax: +91 11 2605 9663.
E-mail addresses: javedaali@yahoo.com, jali@jamiahamdard.ac.in
(J. Ali).
URLs: http://www.scopus.com/authid/detail.url?authorId=25641028400,
http://orcid.org/0000-0001-5308-0655 (J. Ali).
Peer review under responsibility of Faculty of Pharmacy, Cairo
University.
http://dx.doi.org/10.1016/j.bfopcu.2015.10.001
1110-0931  2015 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.Bharti Gaba, Mohammad Fazil, Saba Khan, Asgar Ali, Sanjula Baboota,
Javed Ali *Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, IndiaReceived 22 April 2015; accepted 4 October 2015
Available online 29 October 2015KEYWORDS
Terbinaﬁne HCl;
Nanostructured lipid carrier;
Topical delivery;
Fungal infectionAbstract The main aim of the present study was to develop and evaluate Terbinaﬁne HCl (TH)-
loaded nanostructured lipid carrier (NLC) for the treatment of fungal infection via topical
administration. Fungal infections are tremendously widespread and the treatments are effective
but associated toxicities restrict their use. TH-NLC was prepared using high pressure homogeniza-
tion technique using Glyceryl Monostearate (GMS) as solid lipid, Labrasol as liquid lipid and
Pluronic F-127 as surfactant, binary lipid phase was selected in the ratio 6:4 w/w (solid:liquid lipid
ratio). The mean diameter of optimized TH-NLCs was found to be 128 ± 4.5 nm. Spherical shape
and size were conﬁrmed using scanning electron microscopy (SEM) and transmission electron
microscopy (TEM) analyses. The in vitro release studies showed 92.60 ± 0.87% drug release over
24 h as compared to the marketed formulation which showed only 82.826 ± 0.29%. Ex vivo skin
permeation study showed about 86.35% permeation however from the marketed formulation it
showed 69.41%. The pharmacodynamic studies indicated that TH-NLC (771 ± 41.797 CFUs)
gel efﬁciently reduced the fungal burden in shorter duration of time as compared to marketed
formulation (1558 ± 140.524 CFUs) and dispersion (95,582 ± 2316.619 CFUs) (p value > 0.001).
Therefore, it can be concluded that the developed NLCs showed a sustained release pattern and
reduction of fungal burden in the infected area. Hence, TH-NLC could be a potential alternative
for treatment of topical fungal infection after clinical evaluation in near future.
 2015 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.1. Introduction
In the current scenario, fungal infections are tremendously
widespread. Over billions of people are diagnosed each year
with either topical or severe systemic fungal infections.1
Although, antifungal drugs are effective in treating fungal
infections but they are associated with severe toxicities like
liver damage or they may affect estrogen levels or may cause
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groups are known to have caused anaphylaxis. Terbinaﬁne
Hydrochloride (TH) is a potent antifungal agent of the
allylamine class which selectively inhibits fungal squalene
epoxidase. (Fig. 1) It has a broad-spectrum activity against
yeast, fungi, molds, and dermatophytes and is indicated for
both oral and topical treatments of mycoses. It is typically
administered orally (250 or 500 mg per day) or topically (1%
cream, applied twice daily).2–4
TH has very poor water solubility and is highly lipophilic
(log P 3.3) in nature. The main advantage of this drug is that
it can be used as a topical drug delivery system. The beneﬁts of
topical administration of TH include direct delivery and
targetability to the affected area of the skin, low dose require-
ment and minimized drug related toxicities.5
Lipid based drug delivery systems are nowadays popular as
they are expected to be the promising carriers because of their
potential to increase solubility and improve bioavailability of
poorly water soluble and/or lipophilic drugs.6 The introduc-
tion of advanced generation of lipid nanoparticles named as
NLCs has overcome the general limitations associated with
conventional lipid based formulations and solid lipid nanopar-
ticles (SLNs).7,8 Earlier, SLNs attracted lot of attention as a
drug delivery system9 for they offer the advantages of biocom-
patibility, drug targeting, modiﬁed release and ease of large
scale production.10 However, depending on the drug, various
potential problems can occur, such as drug leaking during
storage and insufﬁcient drug loading. Later on, NLCs are
designed by mixing the solid lipid with the liquid lipid, which
leads to special nanostructures with improved properties for
therapeutic loading, alteration of the drug release proﬁle and
stability.11,12 The major advantage of this type of carrier/
delivery system is its ability to incorporate large quantities of
drugs as a result of formation of a less ordered lipid matrix
with many imperfections.12–16 NLC ensures close contact to
the stratum corneum owing to its unique lipid composition
and smaller particle size, thereby enhancing drug ﬂux through
the skin. Also, because of solidiﬁed lipid matrix, a controlled
release of the therapeutic moiety from these carriers is possi-
ble.17,18 NLCs for the reason that they formed a less ordered
lipid matrix with many imperfections, have the ability to
incorporate large quantities of drugs.19 They are also found
to signiﬁcantly increase skin hydration and exhibit occlusive
properties due to reduction in the transepidermal water loss.20
The primary site of action of Terbinaﬁne is the stratum
corneum in fungal infections residing superﬁcially on the skin
layers.21,22 It possesses minimum inhibitory concentrations
(MIC) of 0.001–0.01 lg/ml and low minimal fungicidalFigure 1 Mechanism of action of Terbinaﬁne Hydrochloride.concentrations of 0.003–0.006 lg/ml. The drug should be pre-
sent in a concentration above its MIC at the site of action for
effective therapeutic action.23 In this context, topical NLC
may prove to be a potential option for increasing the concen-
tration of drug by controlled targeting up to deeper skin layers.
SLNs involve the incorporation of the solid lipid whereas
NLCs involve the drug entrapment into the solid and liquid
lipid mix which may contribute to make it a sustained release
formulation and thereby overcoming the limitation of SLNs.
Topical NLC formulation aims to reach the target site with
required concentration to achieve its therapeutic action with
minimal adverse effects24,25 however stability issues still
remained the point of concern. Several attempts have been
made to enhance the bioavailability of the drug via topical
route. SLN formulations were developed prior to effectively
reducing the fungal burden. SLNs produced showed a signiﬁ-
cant effectiveness when compared to the marketed formula-
tions26,27 Vaghasiya and coworkers prepared Terbinaﬁne
HCl (TH) loaded SLNs using Compritol 888 ATO as lipid
matrix, Pluronic F-127 as stabilizer and distilled water as
dispersion medium using solvent injection technique.27 Also,
Chen and coworkers prepared the SLN formulation by incor-
porating drug in the combination of GMS and Compritol
888.28 Although above stated study ﬁndings highlighted the
advantages of SLN, stability and poor drug loading remained
to be a serious issue of consideration. Therefore NLCs, the
newer generation of SLNs were chosen to overcome these lim-
itations and provide better therapeutic prospects. As a result,
the objective of the present study was to prepare and optimize
TH loaded NLC for topical administration and to assess the
developed formulation for in vitro release, ex vivo permeation
and in vivo (pharmacodynamics) studies which may be found
to be more effective than the SLNs developed before.
2. Materials and methods
2.1. Materials and components
TH was received as a gift sample from Dr. Reddy’s Laboratory
(Andhra Pradesh, India). Precirol ATO 5, Compritol 888 ATO
and Labrasol were obtained from Gattefosse India Pvt. Ltd.
(Mumbai, India), Glyceryl Monostearate was obtained from
CDH, Pvt. Ltd, (Delhi, India), Tween 20 and Tween 80 were
from SDFCL, (Mumbai, India), Castor oil was obtained from
Thomas Baker Pvt. Ltd. (Mumbai, India), Oleic acid, Span 80,
HPLC Methanol, HPLC Water and Glacial Acetic Acid were
obtained from S.D. Fine Chemicals, Ltd. (Mumbai, India),
Pluronic F 188 and Pluronic F 127 were from BASF
(Ludwigshafen, Germany).
2.2. Experimental design of nanostructured lipid carrier (NLC)
In the present study, Box–Behnken statistical design with 3
factors, 3 levels, and 17 runs was employed for the optimiza-
tion study using Design-Expert software (Design-Expert
8.0.0.6, State-Ease Inc., Minneapolis, USA). Percent lipid con-
centration (A), percent surfactant concentration (B) and num-
ber of cycles of high pressure homogenizer (HPH) (C) were
selected as independent variables and they were set at
high-, medium- and low levels on the basis of the results of
initial trials. Table 1 summarizes the coded values of different
Table 1 Variables and their constraints in Box–Behnken
design.
Variables Constraints
Lower
limit
Upper
limit
Independent variables
A=Quantity of lipid concentration (%) 1 2
B = Quantity of surfactant
concentration (%)
0.5 1.5
C = Numbers of HPH cycles 4 6
Dependent variables Goals
R1= Particle size (nm) Minimize
R2 = Entrapment eﬃciency (%) Maximize
R3 = Drug loading (%) Maximize
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were prepared and characterized for particle size (R1), entrap-
ment efﬁciency (R2) and drug loading (R3) which were chosen
as response parameters Table 1. This design explicates the
main effects, interaction effects and quadratic effects of the
independent variables on the formulation characteristics.
2.3. Screening of components
As such there is no standard method set for the selection of the
lipids; however the procedure and results are in accordance
with the previous research articles.29,30
2.3.1. Screening of liquid lipids (oils) and surfactants
The solubility of TH in various liquid lipids (Castor oil, Oleic
acid, Labrasol, Isopropyl myristate, Cremophore EL) and sur-
factants (Tween 20, Tween 80, Span 80, Pluronic F 188 and
Pluronic F 127) was determined by adding excess amounts of
drug in 3 ml of oils in small vials. The vials were tightly stop-
pered and were continuously stirred to reach equilibrium for
72 h at 25 C in a mechanical shaker. After that, the mixtures
were centrifuged using High Speed Centrifuge (3K30, SIGMA,
Germany) at 5000 rpm for 30 min at 37 C.31 The supernatant
was separated, dissolved in methanol and solubility was quan-
tiﬁed by UV Spectrophotometer at 223 nm. The solubility
studies were done in triplicate and results reported as ±SD.
2.3.2. Screening of solid lipids
The solubility determination of TH in various solid lipids (Pre-
cirol ATO 5, Compritol 888 ATO, Glyceryl Monostearate,
Gelucire) was performed by adding TH in increments of
1 mg until it failed to dissolve further in the molten solid lipids
(which were heated at 5 C above their melting point). The
amount of solid lipids required to solubilize TH was calcu-
lated. The experiment was conducted in triplicate.32
2.4. Selection of a binary lipid phase
The solid and liquid lipid with the best-solubilizing potential
for TH were mixed in different ratios viz., 95:5, 90:10, 85:15,
80:20, 70:30, and 60:40 in order to establish the miscibility of
the two lipids. Lipid mixtures were agitated at 200 rpm for1 h at 85 C using a magnetic stirrer (Remi instruments Ltd.,
Mumbai, India). The miscibility between the two components
was investigated by smearing a cooled sample of the solid
mixture onto a ﬁlter paper, followed by visual observation to
determine the presence of any liquid oil droplets on the ﬁlter
paper. A binary mixture exhibiting a melting point above
40 C which did not reveal the presence of oil droplets
on the ﬁlter paper was selected for the development of
TH – loaded NLCs.
2.5. Preparation of NLC
The preparation of aqueous NLC was carried out according to
the method reported by Muller and co-workers.9 Accordingly,
the weighed amount of drug was added to the lipid
phase which was heated at 10–15 C above the melting point
of solid lipid and simultaneously, aqueous surfactant solution
was heated at the same temperature (85 C). Then the lipid
mixture was poured in the hot aqueous surfactant solution
using a magnetic stirrer (Remi instruments Ltd., Mumbai,
India) at 12,000 rpm for 30 min, to prepare the primary emul-
sion. This primary emulsion was converted to the NLC system
using high pressure homogenizer (Stansted Fluid Power Ltd.,
Harlow, UK) at 15000 PSI. The obtained NLC dispersion
was cooled down to room temperature. The NLC dispersion
was lyophilized for long term stability. Mannitol (5% w/v)
was added as cryoprotectant. The samples were frozen at
-78 C for 10 h followed by lyophilization for 36 h. The
lyophilized formulation was reconstituted with phosphate
buffer pH 6.8 as per the requirements for later experiments.
2.6. Optimization and characterization NLC
2.6.1. Particle size and particle size distribution
The particle size analysis of NLC formulations was done by
photon correlation spectroscopy (PCS) with a Zetasizer
(Malvern Instruments, Worcestershire, UK). The PCS pro-
vides the mean particle size (z-average) and the polydispersity
index (PDI) as a measure of the width of the distribution. The
analysis was performed after dilution with double distilled
water followed by ﬁltration through Whatman ﬁlter paper.
2.6.2. Entrapment efficiency (EE) and drug-loading capacity
(DL)
For EE and DL, the drug-loaded NLC dispersion was uni-
formly mixed by gentle shaking. 1.0 ml of this dispersion was
diluted with 9.0 ml methanol, centrifuged using High-Speed
Refrigerated Centrifuge (3K30, SIGMA, Germany) for
45 min at 15,000 rpm and then ﬁltered using Millipore mem-
brane (0.2 lm). The analytical method employed was as per
the method reported by Baboota and coworkers.33 Accord-
ingly, UV absorption spectra of stock solution (10 lg/ml) were
scanned for absorbance in the region of 400–200 nm at
223 nm. Serial dilutions of standard solutions were prepared
and absorbance was recorded at 223 nm. The calibration curve
was prepared and the method was validated. The ﬁltrate was
collected and appropriately diluted with methanol and mea-
sured spectrophotometrically (Shimadzu, model UV-1601,
Kyoto, Japan) at kmax of 223 nm. The percent entrapment efﬁ-
ciency (EE%) was calculated using the following equation.34
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WðTotalÞ  100
DL% ¼WðTotalÞ WðFreeÞ
WðLipidÞ  100
Wtotal, Wfree and Wlipids are the weight of drug added in
system, analyzed weight of drug in supernatant and weight
of lipid added in system, respectively.
2.7. Evaluation of NLC
2.7.1. Transmission electron microscopy (TEM)
The Particle Size (PS) was determined for the NLCs using
TEM (TECNAI-G2, 200 kV, HR-TEM, FEI, The Netherlands).
A drop of NLC was placed on a parafﬁn sheet and carbon
coated grid was put on sample and left for 1 min to allow
NLC to adhere on the carbon substrate. The remaining NLC
was removed by adsorbing the drop with the corner of a piece
of ﬁlter paper. Then the grid was placed on the drop of
phosphotungstate (1%) for 10 s. The remaining solution was
removed by absorbing the liquid with a piece of ﬁlter paper
and samples were air dried and examined by TEM.
2.7.2. Scanning electron microscopy (SEM)
The shape and surface characteristics of NLCs were deter-
mined by SEM using gold sputter technique (ZEISS EV40,
Carl Zeiss NTS, North America). Samples of NLC were
dusted onto a double-sided tape on an aluminum stub. The
stubs containing the sample were coated with gold using a cool
sputter coater (Polaran E 5100) to a thickness of 400 A0.
Photomicrographs were taken at the accelerated voltage of
20 kV and chamber pressure of 0.6 mmHg.
2.7.3. Differential scanning calorimetry (DSC)
Differential scanning calorimetry (DSC) and XRD were
employed to identify the crystal form of TH dispersed in the
lipid matrix. Thermograms were recorded by means of DSC
for the identiﬁcation of crystallinity. For calorimetric measure-
ments, standard aluminum pans with accurately weighed
1–2 mg samples were tightly sealed. Samples were heated at a
scanning rate of 10 C/min over a temperature range between
40 C and 400 C. An empty pan was used as reference. An
inert atmosphere was maintained by purging with nitrogen.
2.7.4. X-ray diffraction study (XRD)
XRD pattern of drug, and freeze dried NLC were obtained
using X-ray diffractometer (Bruker D 8 ADVANCE, Bruker,
USA) and Cu as a radiation source. The range of scan used
was 0–50 of the diffraction angle 2h. XRD pattern was
measured with a voltage of 40 kV and a current of 30 mA.
Equivalent amounts of samples were used in the XRD study.
2.8. Preparation of TH NLC gels
The gels were prepared by dispersing 1% w/w Carbopol 940
in the selected NLC formulations and subsequently neutraliz-
ing the Carbopol dispersion using triethanolamine (TEA).
The ﬁnal concentrations of TH in the NLC gels were main-
tained at 0.5, 1 and 1.5% w/w and were coded as NLC1,
NLC2 and NLC3 respectively.2.9. Characterization of TH NLC gels
2.9.1. Viscosity
The viscosity of the different NLC samples was obtained by
Brookﬁeld viscometer (Brookﬁeld engineering laboratories,
Inc., MA, USA) with spindle No. 6 at 10 rpm at temperature
of 37 ± 0.5 C.
2.9.2. Measurement of pH
100 mg of the gel formulation was weighed in a 50 mL
volumetric ﬂask and then volume was made up with distilled
water to 50 mL (0.2% strength). The pH of the dispersion
was measured using pH meter (pH Tutor Bench Meter,
EUTECH Instruments, Singapore).
2.9.3. Spreadability
0.5 g of gel was placed within a circle of 1 cm diameter
pre-marked on a glass plate, over which second glass plate
was placed. A weight of 500 g was allowed to rest on the upper
glass plate for 5 min. The increase in the diameter due to gel
spreading was noted.
2.9.4. Extrudability
The test involves measuring the quantity of gel extruded from
collapsible tube on application of constant weight. A closed
collapsible tube containing 20 g of gel was pressed by applying
a constant load of 1 kg at the crimped end. When the cap was
removed, gel extruded until pressure dissipated. The extruded
gel was collected and weighed.
2.10. In vitro drug release studies
In vitro drug release studies of NLC were performed using dial-
ysis bag technique. The activation of dialysis membrane was
carried out. The experiments were carried out under sink con-
ditions. 10 mg of each formulation i.e., TH dispersion, NLC,
marketed formulation was loaded into a cellulose membrane
dialysis bag (molecular weight cut-off 12,400, Sigma–Aldrich
Co., St. Louis, MO, USA), immersed in 200 mL of pH 7.4
phosphate buffer containing 0.8% tween 80 solution magneti-
cally stirred at 32 C at pH 7.4. Samples were taken at prede-
termined intervals from the receiver solution, replaced with
equal volumes of fresh solvent, and spectrometrically assayed
for drug concentration at kmax 223 nm. The correction for
the cumulative dilution was calculated. The release studies
were performed in triplicate.35,36
2.11. Ex vivo permeation studies
Ex vivo study was carried out using full thickness rat abdom-
inal skin. In this work due to easy availability, the skin of
albino rat was used. The species used was Wistar Albino Rats
of 18–25 weeks and weight of 150–200 g of either sex. The
abdominal skin was removed and dipped into phosphate
buffer saline (PBS) pH 7.4. Hairs were removed from the skin
by hair removal cream. The subcutaneous fat was removed
with a scalpel. The skin was mounted on the Franz diffusion
cell and the receptor chamber was ﬁlled with 20 ml diffusion
medium. The diffusion medium consisted of PBS pH 7.4
containing 0.8% v/v of Tween-80. The skin was positioned
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upward in the receptor chamber and then the donor chamber
was clamped in place. The excess skin was trimmed off and the
whole assembly was put on a magnetic stirrer to continuously
stir the medium present in the receptor compartment. The dif-
fusion cell was placed in the diffusion apparatus to stabilize at
32 C. The test formulations (NLCs based gel and commercial
formulation i.e., 1% cream) equivalent to 20 mg drug were
applied to the skin. Samples were withdrawn from the receptor
compartment at predetermined time intervals, and immedi-
ately replaced with fresh diffusion medium. The studies were
performed for 12 h according to the clinical application time
and samples were analyzed spectrophotometrically at kmax
223 nm. Drug permeation, Flux (lg/cm2/h) and permeability
coefﬁcient (Pb) [cm2h1] studies were calculated using the
formulas mentioned.33,37
Cumulative amount of drug permeated
¼ concentration
lg
ml
  dilution factor
Area of permeation cell
 volume of receiver chamber
Flux ¼ cumulative amount of drug permeated
timeðhrsÞ
Pb ¼ Flux
drug concentration in donor cell2.12. In vivo pharmacodynamic studies
The pathogen free 18-–25 week old male albino rats weighing
180–200 g were used for the experiment. All animal experi-
ments were approved by IAEC (Jamia Hamdard, New Delhi,
India). Animals received a normal, pathogen free diet and
water. Animals were divided into four groups and each group
consisted of three animals. Group 1 was control (untreated
rats), groups 2, 3 and 4 consisted of rats induced with fungal
infection and treated with TH loaded NLCs based Carbopol
940 gel, commercial TH cream (commercial formulation i.e.,
1% cream) and TH dispersion in water, respectively. All the
materials used were sterilized by autoclaving at 121 C and
15 psi for 30 min.
2.12.1. Test organism and preparation of fungal inoculum
Culture of Candida albicans ATCC 10231 was obtained from
Microbiology Department, HIMSR, Jamia Hamdard, New
Delhi, India. This strain was stored on Sabouraud dextrose
agar (SDA) slant during the study and subculture was used
to induce infections. The parent culture of C. albicans was sub-
cultured on 3% Sabouraud dextrose broth and allowed to
grow for 2 days at 27 C. The ﬁnal conidial suspension of
C. albicans was prepared in sterile saline containing 0.05%
w/v Tween-80. The conidial suspension was adjusted to the
density of 1  106 CFU/ml by counting under hemocytometer
and it was used as innoculum.38
2.12.2. Induction of cutaneous candidiasis infection
Hairs were removed by hair removal cream from an area
(2 cm2) on the back of the albino rats to make a hairless
square. On the following day, the skin was slightly abradedwith sandpaper. The naked skin of the rat was disinfected with
ethyl alcohol and sterile cotton impregnated with 0.1 ml of
conidial suspension was ﬁxed to the animal skin by adhesive
tape and kept for 3 days.39 The skin tissue of the infected site
was excised using sterile scalpel at various time intervals,
implanted onto 3% sabouraud dextrose broth (containing
4% agar powder) plate and incubated at 27 C for 2 days.40
Suitable dilution was done to achieve countable colony
forming unit (CFU) growth. CFU was counted using a digital
colony counter based on countable CFU values. This was
continued till induction of fungal infection was conﬁrmed
based on the number of CFUs.
2.12.3. Treatment regimen
TH loaded NLC based Carbopol gel, TH dispersion and
commercial formulation i.e., 1% cream (equivalent to 2 mg
drug on daily basis) were applied topically and the results in
terms of reduction in fungal burden were compared. Treat-
ment was started after conﬁrmation of induction of fungal
infection by counting the number of CFUs. After initiation
of treatment, quantitative analysis of fungal burden was
performed by the above mentioned procedure.3. Results and discussion
3.1. Screening of components
The criteria for selection of excipients for developing TH-NLC
include pharmaceutical acceptability, nonirritant and non sen-
sitizing to the skin and that they fall under GRAS (generally
regarded as safe) category. Solubility of various solid lipids,
liquid lipids and surfactants in TH is given in Fig. 2 and
Table 4. As per the results of solubility studies, TH exhibited
maximum solubility in Glyceryl Monostearate (GMS) (69.8
± 1.57 mg/ml), Labrasol (124 ± 0.35 mg/ml) and Pluronic
F-127 (92.1 ± 2.09 mg/ml). Therefore, TH-NLC was prepared
using GMS as solid lipid, Labrasol as liquid lipid and Pluronic
F-127 as surfactant. Based on the visual observation of smear
test, binary lipid phase was selected in the ratio 6:4 w/w (solid:
liquid lipid ratio) for designing NLC.3.2. Optimization and characterization of NLC
On the basis of deﬁned constraints for each independent vari-
able, the Design Expert software automatically generated the
optimized formula, Table 2. The experimental values were
obtained by preparing 17 batches of drug loaded NLCs and
simultaneously evaluating them for response parameters (PS,
EE and DL) according to the optimized formula generated
by the software. Calculation of percentage prediction was done
to determine the accuracy of prediction by the software and
the utility of the experimental design for modifying the NLCs
with desirable parameters.
When the experimental values of responses for 17 runs were
ﬁtted to different models of Box Behnkehn design, it was
observed that the best-ﬁtted model for all of the three depen-
dent variables was the quadratic model with coefﬁcient of
correlation (R2) nearly equal to 1. The summary of results of
regression analysis for the three responses is given in Table 3.
The ‘‘Predicted R2” was in reasonable agreement with the
‘‘Adjusted R2” values for all response parameters (as shown
Figure 2 Solubility of various components with ±S.D.
Table 2 The Box–Behnken experimental design matrix for the formulation and optimization of NLCs.
Exp.
run
Coded values Actual values Dependent factors
Lipid
conc.
(A)
Surfactant
conc. (B)
No. of HPH
cycles (C)
Lipid conc.
(A) (%)
Surfactant
conc. (B) (%)
No. of HPH
cycles (C)
PS (nm) n= 3
(±SD)
EE (%)
n= 3
(±SD)
DL (%)
n= 3
(±SD)
1 +1 1 0 2.00 0.50 5.00 319.62 ± 15.21 74.32 ± 6.53 4.35 ± 2.34
2 0 1 0 1.50 1.00 5.00 126.01 ± 8.67 84.32 ± 8.21 17.84 ± 1.38
3 1 0 1 1.00 1.00 4.00 208.56 ± 12.24 74.21 ± 6.52 7.38 ± 3.86
4 0 +1 +1 1.50 1.50 6.00 198.31 ± 8.92 72.16 ± 4.98 10.77 ± 3.12
5 0 0 +1 1.50 1.50 4.00 310.64 ± 9.53 66.33 ± 6.45 1.98 ± 1.29
6 0 0 0 1.50 1.00 5.00 124.72 ± 7.86 83.93 ± 5.82 11.32 ± 2.96
7 0 0 1 1.50 0.50 4.00 276.1 ± 12.34 70.45 ± 6.34 5.73 ± 2.37
8 +1 0 0 2.00 1.00 4.00 175.65 ± 12.65 77.84 ± 4.46 5.19 ± 2.14
9 0 1 0 1.50 1.00 5.00 127.08 ± 6.92 80.42 ± 6.21 11.75 ± 3.12
10 1 1 1 1.00 0.50 5.00 238.65 ± 14.86 73.1 ± 3.45 10.02 ± 2.75
11 1 +1 0 1.00 1.50 5.00 344.23 ± 11.23 63.25 ± 5.67 3.5 ± 4.23
12 0 +1 +1 1.50 0.50 6.00 282.25 ± 7.52 73.12 ± 6.72 9.56 ± 1.59
13 +1 +1 0 2.00 1.50 5.00 190.42 ± 4.98 72.91 ± 6.53 10.98 ± 2.34
14 0 0 0 1.50 1.00 5.00 129.24 ± 6.54 79.89 ± 8.21 11.21 ± 1.38
15 1 0 0 1.00 1.00 6.00 154.1 ± 8.43 77.27 ± 6.52 10.86 ± 3.86
16 0 0 0 1.50 1.00 5.00 121.34 ± 6.55 82.16 ± 4.98 12.65 ± 3.12
17 +1 0 0 2.00 1.00 6.00 132.12 ± 11.72 79.02 ± 6.45 11.42 ± 1.29
Table 3 Optimization constraints selected.
Variables Constraints
Lower
limit
Upper
limit
Goal
Independent variables
A=Quantity of lipid
concentration (%)
1 2 In range
B = Quantity of surfactant
concentration (%)
0.5 1.5 In range
C = No. of HPH cycles 4 6 In range
Dependent variables
R1= Particle size (nm) 121.34 344.23 Minimize
R2 = Entrapment eﬃciency (%) 63.25 84.32 Maximize
R3 = Drug loading (%) 1.98 17.84 Maximize
152 B. Gaba et al.in Table 3). The Model F-value implies the signiﬁcance of the
model which was signiﬁcant for all response parameters
(Table 3).The following polynomial equations were generated by the
statistical analysis of the results:
PS ¼ þ125:68 15:97A 9:13B 25:52C 58:70AB
þ 2:73AC 29:62BCþ 24:17A2 þ 123:38B2 þ 17:76C2:
EE ¼ þ82:14þ 2:03A 2:04Bþ 1:59Cþ 2:11AB 0:47AC
þ 0:79BC 2:34A2  8:91B2  2:72C2:
DL ¼ þ12:95þ 0:023A 0:30Bþ 2:79Cþ 3:29ABþ 0:69AC
þ 1:24BC 2:02A2  3:72B2  2:22C2:
where A, B and C represent the coded values of the percent
lipid concentration, percent surfactant concentration and
number of HPH cycles respectively.
Only statistically signiﬁcant (p< 0.05) coefﬁcients are
included in the equations. A positive value in polynomial
Table 4 Summary of results of regression analysis for responses.
Response Model R2 Adjusted R2 Predicted R2 F-value SD (±) % CV Mean
PS 2F1 0.9815 0.9704 0.9099 88.28 4.44 3.57 124.52
DL Quadratic 0.9822 0.9593 0.7209 42.87 1.02 11.74 8.65
EE Quadratic 0.9805 0.9553 0.7513 39.03 1.42 1.72 80.58
Figure 3 (A) Response surface plot of factor C vs. A against PS; (B) response surface plot of factor B vs. A against PS; (C) response
surface plot of factor C vs. B against PS.
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tion, while a negative value corresponds to an inverse relation-
ship between the factor and the response. In accordance with
the above stated equation for PS, an increase in the number
of HPH cycles led to a very signiﬁcant decrease in particle size
of NLC formulation. Also, as the concentration of total lipid
and surfactant increases, the particle size decreases. In the case
of EE, it was noticed that an increase in concentration of total
lipid resulted in increased EE. The possible reason behind this
could be that higher lipid content prevents the escape of drug
to outer milieu by effectively enclosing it.41 However the
increase in surfactant concentration decreases the %EE of
drug in NLC which might be due to the decrease in particle
size of NLC by surfactant resulting in a decrease in overallFigure 4 (A) Response surface plot of factor C vs. B against EE; (B
surface plot of factor C vs. A against EE.accommodation space for drug. Moreover, an increase in the
number of HPH cycles led to a signiﬁcant decrease in EE
which might be again due to the decrease in particle size.
For DL, an increase in the amount of total lipid causes a
non-signiﬁcant increase in % drug loading whereas an increase
in surfactant concentration decreases drug loading non
signiﬁcantly. An increase in HPH cycles was found to have a
signiﬁcant effect on DL.
The three-dimensional (3D) response surface graphs which
depict the interaction effects of the independent variables on
the responses are shown in Fig. 3–5. The selection of optimiza-
tion constraints is represented in Table 5. The predicted and
experimental values obtained based on optimized formula
generated by Design Expert software are seen in Table 5.) response surface plot of factor B vs. A against EE; (C) response
Figure 5 (A) Response surface plot of factor C vs. B against DL; (B) response surface plot of factor C vs. A against DL; (C) response
surface plot of factor B vs. A against DL.
Table 5 Predicted and experimental values obtained based on optimized formula generated by Design Expert software.
Factors Responses
Predicted values based on optimized formula
Quantity of lipid
concentration (%)
Quantity of Surfactant
concentration (%)
No. of HPH
cycles
Particle size
(nm)
Entrapment eﬃciency (%) Drug loading (%)
1.613 1.009 5.501 114.660 82.521 13.793
Experimental values based on optimized formula
Quantity of lipid
concentration (%)
Quantity of surfactant
concentration (%)
No. of HPH
cycles
Particle size (nm) Mean Entrapment eﬃciency
(%) (±S.D)
Mean drug loading
(%) (±S.D)
1.5 1.00 6.00 126.00 80.24 ± 4.56 14.26 ± 1.82
Percentage prediction error = 9.89 2.764 3.386
154 B. Gaba et al.3.2.1. Particle size and polydispersity index
The optimized NLCs were in the nanometric size range (128
± 4.5 nm) with low polydispersity index (0.211 ± 0.012)
(Fig. 6). The presence of 40% oil in the NLC lipid matrixFigure 6 Particle size and particle size distributioled to a small mean diameter of NLC. It was usually observed
that on increasing the content of oil in NLC the mean particle
size decreases. Furthermore, the surfactant also greatly inﬂu-
ences the particle size of formulation by causing stabilization.9n of optimized drug loaded NLC formulation.
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after freeze-drying the size was 131.33 ± 3.60 nm; similarly
there was a slight increase in PDI from 0.203 ± 0.012 before
freeze-drying to 0.323 ± 0.022 after freeze-drying.
3.2.2. Entrapment efficiency (%) and drug loading (%)
The EE and DL of optimized TH-NLC were found to be 80.24
± 4.56 and 14.26 ± 1.82 which were attributable to the exclu-
sive matrix structure of NLCs. In NLC, the solid lipid matrix
encloses tiny oil section in which drug solubility is considerably
higher which increases their total drug loading capacity. There-
fore the liquid lipids present in NLCs affect their entrapment
efﬁciency to a great extent by creating imperfections in a highly
ordered crystal matrix and consequently providing sufﬁcient
space for a large amount of drug to lodge successfully.9
3.3. Evaluation of NLC
3.3.1. Transmission electron microscopy (TEM)
The TEM studies were carried out to get more insights into the
morphology of the NLC systems. From the study it was
observed, that after loading the drug into placebo, the particle
size of the formulation increased. This might be due to the
accommodation of the drug in sufﬁcient space in the lipid
matrix. The TEM images (Fig. 7(a)) show the drug enclosed
in the lipid matrix. The TEM images of TH-NLC show uni-
form size distribution of lipid nanoparticles having coarsely
spherical shape. The uniformity in particle size distribution
correlates with the small PDI (0.2) obtained via photon corre-
lation spectroscopy. The particle size after the TEM study was
found to be in the range of 100–140 nm.
3.3.2. Scanning electron microscopy (SEM)
The SEM photomicrograph (Fig. 7(b)) revealed that the NLCs
were spherical with more or less smooth surface. Occasional
clumps were also observed in some of the images which might
arise from problem associated with the shrinkage of NLCs
during drying or concentration of dispersion medium.
3.3.3. Differential scanning calorimetry (DSC)
The DSC thermogram of pure drug and patterns of freeze-dried
TH-NLC are shown in Fig. 8(a) and (b). A shift in the peak was
seen (Fig. 8(b)) which may be due to the interaction of the drug
with the lipid matrix. The DSC thermogram demonstrates theFigure 7 TEM image (A) of optimized formulationdisappearance of drug peak in the formulation (NLC) which
suggests that the drug is completely enclosed inside the
lyophilized drug-loaded NLC. DSC curves of the excipient were
compared to the already reported curves in the literature.42–44
3.3.4. X-ray diffraction studies (XRD)
TH powder was highly crystalline as evident from sharp peaks
seen at the 2h value of TH in the X-ray scan (Fig. 9 (b)). Fig. 9
(a) shows the XRD patterns of freeze-dried TH loaded NLC.
XRD of TH-NLC conﬁrmed that the individual components
have partially lost their crystalline nature when incorporated
into NLC. The X-ray diffraction of the excipients of blank
NLC which were available in the literature was accordingly
compared.42–44 These results are also in accordance with the
results established by earlier workers.45
3.4. Preparation of TH-NLC gel
The optimized NLC gel was formulated into gel by the use of
0.5%, 1% and 1.5% carbomer 940. Gel (1%) was found to be
suitable for gelling the NLC because of desirable consistency.
Table 6.
3.5. Characterization of TH-NLC gel
3.5.1. Spreadability
Spreadability means area to which the gel readily spreads on
application to the skin or affected part. Formulation (0.5 g)
was placed within a circle of 1 cm diameter pre-marked on a
glass plate over which a second glass plate was placed. A
weight of 500 g was allowed to rest on the upper glass plate
for 5 min. The increase in the diameter due to spreading of
the test formulation was 6.7 ± 0.07 cm. The obtained value
indicated a good spreadability of the obtained gel prepara-
tions. Spreadability is an essential property of topical formula-
tions from the point of view of the patient compliance. In fact,
gel application on the inﬂamed or diseased skin would be more
comfortable if it can be spread easily.
3.5.2. Viscosity
The viscosity of the formulations was determined using
Brookﬁeld viscometer (Brookﬁeld Engineering Laboratories,
Inc., Middleboro, MA, USA). The viscosity of the optimized
formulation was found to be 501 ± 0.57 cps.and (B) SEM image of drug loaded formulation.
Figure 9 Xrd (A) drug loaded NLC; (B) XRD of pure drug.
Figure 8 DSC Curve (A) Terbinaﬁne Hydrochloride; (B) optimized formulation.
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Table 6 Characteristics of gelling agents for NLC gel.
S. No. % of Carbomer Gel formation Spreadability
1. 0.5 No gel formed –
2. 1 Formed Good
3. 1.5 Formed Poor
Figure 11 Comparative ex vivo permeation study of NLCs and
drug solution.
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The apparent pH of the gel was determined using pH meter
(pH Tutor Bench Meter, EUTECH Instruments, Singapore)
in triplicate at 25 C. pH of the optimized NLC was found
to be 6.3 ± 0.04. The pH of the NLC-loaded gel was within
the acceptable range for topical formulations and compatible
with the pH of the skin.
3.6. In vitro release study
The in vitro release proﬁle curves obtained by the dialysis
method from TH loaded NLC gel, drug dispersion and
commercial topical marketed product of TH which was used
as reference for comparison were investigated over 24 h and
comparative results are shown in Fig. 10.
It was apparent that TH released in vitro showed an initial
rapid release followed by slow drug release. The initial rapid
release of drug may be due to the release of TH from the
NLC surface, while, at a later stage TH was constantly
released from the solid lipid core of NLCs. Fig. 10 shows the
comparative release proﬁle of optimized NLC, dispersion
and commercial topical product of TH where the dispersion
showed the faster release in comparison of the NLC gel and
commercial formulation. However, the release of the NLC is
greater (92.60 ± 0.87%) and faster than the release of the
marketed formulation cream (82.2 ± 0.69%) which might be
due to the presence of liquid lipid (oils) in the NLC system
with improved drug solubilizing and release potential.
NLC showed a higher in vitro drug release and therefore
a higher cumulative amount of permeation than market
preparation because of its occlusive properties. During theFigure 10 Comparative in vitro release of TH loadedpreparation of NLCs, cooling from high temperature to room
temperature favors the enrichment of the drug in the outer
layers of the particles resulting in superﬁcial entrapment caus-
ing initial burst release.46,47 TH entrapped deep within the
nanoparticles sustains the release to more than 24 h. Also,
after lipid crystallization, the solubility of oil in solid lipid
exceeded; hence, oil precipitates leading to formation of ﬁne
droplets of oil incorporated in solid lipid thereby providing
prolonged release.48
3.7. Ex vivo permeation studies
The purpose of the present study was to target the drug into
the skin with controlled release effect. Drug penetration into
certain layers of the skin can be achieved using NLCs as a
consequence of the creation of a supersaturated system.15
Ex vivo drug penetration studies were performed for NLC
based gel and commercial formulation i.e., 1% cream. The
cumulative amount of drug permeated through the skin was
23.16 ± 2.33% from NLC based gel as compared to 16.72
± 3.67% from marketed preparation (Fig. 11). After 12 h,
69.41 ± 1.85% of the drug was retained in the skin from
marketed preparation as compared to 83.65%± 2.51 from
NLC based gel. The drug was dispersed within the lipid matrixoptimized NLC, dispersion and marketed cream.
Table 7 Quantitative analysis of fungal burden (n= 3).
Group Formulation CFU on diﬀerent days (CFUs)
0 1 3 5
Group-I Control – – – –
Group-II TH loaded NLC 2,56,000 ± 3,605.551 94,270 ± 2,825.678 5,542 ± 169.02 771 ± 41.797
Group-III Marketed formulation 2,56,000 ± 3,605.551 1,08,855 ± 4,852.473 87,581 ± 2,012.106 1558 ± 140.524
Group-IV TH Dispersion 2,56,000 ± 3,605.551 1,77,308 ± 2,179.077 1,05,597 ± 1,792.152 95,582 ± 2316.619
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adhered to the skin, further increasing the contact time.17
Therefore, the enhanced TH retention in the skin is mainly
attributed to the NLCs, their size and bioadhesive properties.
Also, the fact that the drug diffusion through the skin was less
in the case of NLC based gel than the marketed formulation
indicated its skin targeting ability, which is desirable for effec-
tive therapy. By formulating NLC based drug delivery system,
the drug can be targeted to the skin with its reduced systemic
access and reduced side effects. NLCs are formulated using
lipids which are solid at ambient temperature and application
of NLCs incorporated into gel may induce structural change of
particle structure due to evaporation of water resulting in the
transition of lipid matrix into a highly ordered structure caus-
ing drug expulsion.47 From this, it could be concluded that
NLCs may play an important role in controlling the release
of TH from NLCs as well as targeting of drug to the skin.
The amount of drug retained in the skin for NLC based gel
was found to be signiﬁcantly higher as compared to marketed
formulation (p value > 0.001). This dermal retention of TH
was attributed to the increased contact with corneocytes, skin
occlusion and sustained release owing to the properties of
NLCs. Due to their small particle size, NLCs make closer
contacts with superﬁcial junctions of corneocyte clusters and
furrows present between corneocyte islands and favor accumu-
lation for several hours, allowing sustained drug release which
is already studied by Roman and coworkers and Cevc and
associates.49,503.8. In vivo pharmacodynamic studies
Fungal burden was quantitatively analyzed in terms of colony
forming units (CFUs) after initiation of the treatment. CFUs
were counted using a colony counter (Microbiology lab, Jamia
Hamdard, New Delhi, India). Table 7 gives the quantitative
analysis of fungal burden.
Control group did not show any growth, as infection was
not induced to this group. Group treated with NLCs showed
a signiﬁcant decrease in fungal burden after 5 days (771
± 41.797 CFUs) (p value < 0.001) as compared to CFUs
before initiation of treatment (2,56,000 ± 3,605.551 CFUs)
(p value < 0.001). Group treated with marketed formulation
also showed a signiﬁcant decrease in fungal burden after
5 days (1558 ± 140.524 CFUs) (p value < 0.001), but it was
higher as compared to the group treated with developed
formulation. Also, the TH dispersion in water showed an ini-
tial reduction in fungal burden after which it almost came to a
steady state. These results showed that the NLC reduced the
fungal burden in a shorter duration of time as compared to
marketed formulation and dispersion. Thus, TH was found
to be more effective when formulated as NLC based gelbecause of improved contact, adhesion, occlusion and sus-
tained release.
4. Conclusion
In the present study, TH loaded NLCs were successfully pre-
pared using GMS as solid lipid, Labrasol as liquid lipid, Pluro-
nic F-127 as stabilizer using HPH technique. The topical
delivery of TH to the skin by means of NLCs could possibly
minimize its systemic access and side effects. Furthermore,
TH loaded NLCs were capable of reducing the fungal burden.
Therefore, it can be concluded that TH-NLC demonstrated to
be potential formulation approach for treating fungal infection
in contrast to commercially available product.
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